St. Jude Medical, Inc, STJ Securities Lawsuit

Company:	St. Jude Medical, Inc,
Ticker Symbol:	STJ
Class Period:	Dec-15-10 to Apr-4-12
Date Filed:	Jun-14-12
Lead Plaintiff Deadline:	Aug-13-12
Court:	District of Minnesota
Allegations:

Radnor, PA: A securities class action lawsuit has been filed in the United States District Court for the District of Minnesota on behalf of purchasers of the securities of St. Jude Medical, Inc, who purchased or otherwise acquired St. Jude securities between December 15, 2010 and April 4, 2012, inclusive (the "Class Period").

The Complaint charges St. Jude and certain of its officers and directors with violations of the Securities Exchange Act of 1934. St. Jude develops, manufactures and distributes cardiovascular medical devices. More specifically, the Complaint alleges that the defendants failed to disclose and misrepresented that the Company's Riata and Riata ST defibrillator leads were associated with short circuits and protruding wires, and that the Company's QuickSite and QuickFlex Left-Ventricular leads also suffered from protruding wires. A "lead" is a wire that connects a defibrillator to the heart.

During the Class Period, the defendants told investors that two of the Company's defibrillator leads, the Riata and Riata ST electrical wire, had been observed to wear through the silicone casing meant to contain them and protrude into the body. St. Jude thereafter discontinued sales of the Riata and Riata ST. However, the defendants failed to disclose the full extent of the problems with its products. First, the defendants failed to disclose that the Riata and Riata ST defibrillator leads were also associated with short circuits unrelated to the protruding wires. Although less frequent than the protrusions, the short circuits were much more dangerous. Second, the defendants failed to disclose that two other leads sold by the company, the QuickSite and QuickFlex Left-Ventricular leads, also suffered from the same protruding wires that plagued the Riata and Riata ST.

On March 27, 2012, The New York Times disclosed the results of an analysis performed by an independent researcher, Dr. Robert Hauser, which indicated that the Riata and Riata ST caused short circuits. However, the defendants vehemently challenged these findings, thus maintaining the artificial inflation in St. Jude's stock.

On April 4, 2012, the defendants finally disclosed that the QuickSite and QuickFlex Left-Ventricular leads also suffered from the same protruding wire defect as the Riata and Riata ST. As a result, sales of the QuickSite and QuickFlex Left-Ventricular leads were also discontinued. Following these disclosures, the closing price of St. Jude's stock dropped from $43.80 to $38.91 over three trading days, a decline of over 11 percent.

If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.

St. Jude Medical, Inc, STJ Securities Fraud Legal Help

If you have suffered from financial losses, you may qualify for damages or remedies that may be awarded in a possible St. Jude Medical, Inc, securities class action lawsuit. Please click the link below to submit your complaint for a free evaluation.
Published on Jun-15-12